The effect of Schizophyllan on the differentiation of osteoclasts and osteoblasts
In this study, its effects on bone cells, particularly osteoclasts and osteoblasts, were examined. We demonstrated that SPG dose-dependently inhibited osteoclastogenesis and reduced gene expression associated with osteoclast differentiation. SPG also decreased bone resorption and F-actin ring formation. This inhibition could have been due to the downregulation of transcription factors c-Fos and nuclear factor of activated T cells 1 (NFATc1) via the MAPKs (JNK and p38), IκBα, and PGC1β/PPARγ pathways. In coculture, SPG lowered osteoclastogenic activity in calvaria-derived osteoblasts by reducing macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL) expression. In addition, SPG slightly enhanced osteoblast differentiation, as evidenced by increased differentiation marker gene expression and alizarin red staining. It also exhibited antiresorptive effects in a lipopolysaccharide-induced calvarial bone loss model. These results indicated a dual role of SPG in bone cell regulation by suppressing osteoclastogenesis and promoting osteoblast differentiation. Thus, SPG could be a therapeutic agent for bone resorption-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.PMID:38604070 | DOI:10.1016/j.bbrc.2024.149860
Source: Cell Research - Category: Cytology Authors: Soo-Ho Kim Keun Ha Park Jun Lee Seoung Hoon Lee Jeong-Hwa Baek Source Type: research
More News: Antidoxidants | Arthritis | Cytology | Genetics | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology | Study